Table 1.
Patient Characteristics and Baseline Quality of Life Scores
| CIMRT n=152 | HIMRT n=151 | p-value | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Age | |||||
| Median (Range) | 67 (45–86) | 67 (49–86) | 0.79 | ||
| Pre-treatment PSA | |||||
| < 10 | 99 | 65.1 | 95 | 62.9 | |
| 10–20 | 40 | 26.3 | 41 | 27.2 | |
| > 20 | 13 | 8.6 | 15 | 9.9 | |
| T-stage | |||||
| T1 | 59 | 38.8 | 61 | 40.4 | 0.77 |
| T2 | 77 | 50.7 | 71 | 47 | |
| T3 | 16 | 10.5 | 19 | 12.6 | |
| NCCN Risk Group | |||||
| Low | 24 | 15.8 | 22 | 14.6 | 0.96 |
| Intermediate | 85 | 55.9 | 86 | 57 | |
| High | 43 | 28.3 | 43 | 28.5 | |
| Gleason Score | |||||
| 6 | 51 | 33.5 | 53 | 35.1 | 0.96 |
| 7 | 72 | 47.4 | 70 | 46.4 | |
| ≥ 8 | 29 | 19.1 | 28 | 28 | |
| ADT | |||||
| No | 81 | 53.3 | 83 | 55 | 0.77 |
| Yes | 71 | 46.7 | 68 | 45 | |
| Lymph Node Radiation | |||||
| No | 104 | 68.4 | 103 | 68.2 | 0.97 |
| Yes | 48 | 31.6 | 48 | 31.8 | |
| Race | |||||
| Black | 27 | 17.8 | 11 | 7.3 | 0.02 |
| White | 119 | 78.3 | 134 | 88.7 | |
| Other | 6 | 3.9 | 6 | 4 | |
| Baseline EPIC, Median (Range) | |||||
| Urinary Irritative/Obstructive | 92.86 (39.29–100) | 91.67 (64.29–100) | 0.90 | ||
| Urinary Incontinence | 92.35 (39.5–100) | 100 (52–100) | 0.40 | ||
| Hormone | 93.18 (56.82–100) | 93.18 (54.44–100) | 1.00 | ||
| Sexual | 47.77 (0–93.75) | 53.23 (0–94.23) | 0.70 | ||
| Bowel | 95.54 (58.93–100) | 98.21 (60.71–100) | 0.09 | ||
| Baseline IPSS, Median (Range) | |||||
| Overall | 6 (0–28) | 6 (0–26) | 0.8 | ||
| QoL score | 2 (0–6) | 2 (0–6) | 0.3 | ||
| Baseline EQ5D, Median (Range) | |||||
| EQ5D Index | 1 (0.4–1.0) | 1 (0.51–1.0) | 0.57 | ||
| EQ5D VSAS | 85 (50–100) | 85 (30–100) | 0.17 | ||